Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. NOW
3. TXN
4. TSLA
5. GOOG
6. IBM
7. KNX
8. CSX
9. LVS
10. INTC

Go back to Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

Ionis Pharmaceuticals (IONS) PT Lowered to $86 at Needham

July 9, 2026 12:40 PM EDT

Needham analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $86.00 (from $105.00) while maintaining a Buy rating.

... More